(19) World Intellectual Property Organization International Bureau



A CORRA CONCORD DA COMO CENDO ENTRE ELLON ENDA EN RA CORRAD EN RA CORRAD ELLON EN REPORTADO A CORRAD DE LA REC

(43) International Publication Date 23 June 2005 (23.06.2005)

PCT

(10) International Publication Number WO 2005/055980 A3

(51) International Patent Classification⁷: A61K 47/48

(21) International Application Number:

PCT/US2004/040660

(22) International Filing Date:

3 December 2004 (03.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/527,330

5 December 2003 (05.12.2003) US

(71) Applicant (for all designated States except US): ARRO-GENE, INC. [-/US]; 8631 West Third Street, Suite 800E, Los Angeles, CA 90048 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): LJUBIMOVA, Julia, Y. [US/US]; 11419 Dona Pegita Drive, Studio City, CA 91604 (US). BLACK, Keith, L. [US/US]; 1233 Roberto

Lane, Los Angeles, CA 90077 (US). HOLLER, Eggehard [DE/DE]; Universitatregensburg, 93040 Regensburg (DE).

- (74) Agents: KIRCHANSKI, Stefan, J. et al; Liner Yankelevitz Sunshine & Regenstreif, LLP, 1100 Glendon Avenue, 14th Floor, Los Angeles, CA 90024 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM



(57) Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.

WO 2005/055980 A3



FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 5 January 2006

tnter al Application No PCT/US2004/040660

A CLASS IPC 7	ification of subject matter A61K47/v48		
According 1	to International Patent Classification (IPC) or to both national classific	eation and IPC	
	S SEARCHED	and it c	
Minimum di IPC 7	ocumentation searched (classification system followed by classification $A61K$	on symbols)	
Documentati	ion searched other than minimum documentation to the extent that	such documents are included in the fields se	arched
Electronic o	data base consulted during the international search (name of data base	ase and, where practical, search terms used)	· · · · · · · · · · · · · · · · · · ·
EPO-In	ternal , BIOSIS, CHEM ABS Data, EMBA	SE, WPI Data, PAO	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re	levant passages	Relevant to claim No
X	BULMUS V ET AL: "A new pH-responglutathione-reactive, endosomal membrane-disruptive polymeric carintracellular delivery of biomole drugs" JOURNAL OF CONTROLLED RELEASE, E AMSTERDAM, NL, vol. 93, no. 2, December 2003 (2 pages 105-120, XP004473631 ISSN: 0168-3659 page 111, column 2, paragraph 4; page 108, column 2, paragraph 3 109, column 2	rrier for ecular LSEVIER, 003-12), figure 1	1,2,6, 14, 18-20, 24,25
X Furth	ner documents are listed in the continuation of box C	X Patent family members are listed in	n annex
° Special car	tegories of cited documents	'T' later document published after the inter	national filing date
	nt defining the general state of the art which is not ered to be of particular relevance	or priority date and not in conflict with cited to understand the panciple or the	
	document but published on or after the International	invention "X" document of particular relevance, the cl	
'L' documer	it which may throw doubts on priority clatm(s) or is cited to establish the publication date of another	cannot be considered novel or cannot involve an inventive step when the doc	ument is taken alone
citation	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	Y document of particular relevance, the cl cannot be considered to involve an inv	entive step when the
other i	means	document is combined with one or more ments such combination being obvious in the art	
later th	nt published prior to the international filing date but nan the priority date claimed	"&' document member of the same patent i	family
Date of the	actual completion of the international search	Date of mailing of the international searce	ch report
2	0 October 2005	02/11/2005	
Name and n	nailing address of the ISA European Patent Office, P B 5818 Patentlaan 2 IML - 2280 HV Rijswijk	Authorized officer	
	TeI (+31-70) 340-2040, Tx 31 651 epo πι, Fax (+31-70) 340-3016	Gonzalez Ramon, N	

Inter ial Application No
PCT/US2004/040660

		PCT/US2004/040660		
C(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	ABDELLAOUI K ET AL: "METABOLITE-DERIVED ARTIFICIAL POLYMERS DESIGNED FOR DRUG TARGETING, CELL PENETRATION AND BIORESORPTION" EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 1, 1998, pages 61-73, XP008047861 ISSN: 0928-0987 abstract see conclusions page 63, column 2, paragraph 2; figures 1,2; table 3	1-28		
Y	ZHANG Y. ET AL: "Antisense gene therapy of brain cancer with an artificial virus gene delivery system" MOLECULAR THERAPY, vol. 6, no. 1, July 2002 (2002-07), pages 67-72, XP008054256 abstract	1-28		
Υ	MARTINEZ BARBOSA M. E. ET AL: "Investigation of the degradation mechanisms of polyCmal ic acid) esters in vitro and their related cytotoxicities in J774 macrophages" BIOMACROMOLECULES, vol. 5, December 2003 (2003-12), pages 137-143, XP008054218 page 137, column 1, paragraph 2	1-28		
Y	MING QIAN z. ET AL: "Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway" PHARMACOLOGICAL REVIEWS, vol. 54, 2002, pages 561-587, XP008054257 page 580 - page 581; figure 7; table 4	1-28		
Y	KHAZENZON N M ET AL: "Anti sense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro" MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 2, no. 10, October 2003 (2003-10), pages 985-994, XP002986547 ISSN: 1535-7163 abstract	1-28		

Inter tal Application No
PCT/US2004/040660

		PCT/US2004/040660
C(Continua	atio π) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	OSANAI S ET AL: "Effects of complexation between liposome and poly(malic acid) on aggregation and leakage behaviour" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 9, May 2000 (2000-05), pages 867-876, XP004202452 ISSN: 0142-9612 see conclusions abstract	1-28
Р,Х	LJUBIMOVA J Y ET AL: "608 A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo" EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 2, no. 8, September 2004 (2004-09), page 184, XP004640052 ISSN: 1359-6349 abstract	1-28
A	EP 0 397 307 A (RESEARCH DEVELOPMENT CORPORATION OF JAPAN) 14 November 1990 (1990-11-14) claim 8	1-28
A	WO 00/05270 A (BARRITAULT, DENIS; CARUELLE, JEAN-PIERRE) 3 February 2000 (2000-02-03) page 76; examples 1,18	1-28

information on patent ramuy memoers

Inter al Application No
PCT/US2004/040660

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0397307	Α	14-11-1990	AU	640927	B2	09-09-1993
			ΑU	5469990	A	15-11-1990
			CA	2016505	Al	11-11-1990
			DE	69029006	Dl	05-12-1996
			ES	2098247	T 3	01-05-1997
			JР	2300133	A	12-12-1990
			JР	2517760	B2	24-07-1996
			KR	9206912	в1	22-08-1992
			US	5412072	A	02-05-1995
WO 0005270	A	03-02-2000	AU	4913699	A	14-02-2000
			CA	2337328	Al	03-02-2000
			ΕP	1117695	Al	25-07-2001
			FR	2781485	Al	28-01-2000
			JР	2002521503	T	16-07-2002
			US	2001021758	Al	13-09-2001